These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 31219038)
1. Successful Treatment of Corticosteroid-Refractory Hypereosinophilia With Reslizumab. Coffey K; Fajt ML; Acho M; Gladwin M; Petrov AA J Investig Allergol Clin Immunol; 2019 Jun; 29(3):241-242. PubMed ID: 31219038 [No Abstract] [Full Text] [Related]
2. Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. Buttgereit T; Bonnekoh H; Church MK; Bergmann KC; Siebenhaar F; Metz M J Dtsch Dermatol Ges; 2019 Nov; 17(11):1171-1172. PubMed ID: 31479567 [No Abstract] [Full Text] [Related]
3. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab. Kuruvilla M Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465 [No Abstract] [Full Text] [Related]
4. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Schwartz LB; Sheikh J; Singh A Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230 [TBL] [Abstract][Full Text] [Related]
5. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood. Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468 [TBL] [Abstract][Full Text] [Related]